List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9137716/publications.pdf Version: 2024-02-01



YOUNG LIK KWON

#	Article	IF	CITATIONS
1	Chemically Tuned Intracellular Gene Delivery by Coreâ€Shell Nanoparticles: Effects of Proton Buffering, Acid Degradability, and Membrane Disruption. ChemMedChem, 2022, , .	3.2	2
2	Extracellular vesicles with high dual drug loading for safe and efficient combination chemo-phototherapy. Biomaterials Science, 2022, 10, 2817-2830.	5.4	9
3	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	13.7	262
4	COVID-19: An unprecedented challenge and an opportunity for change. Advanced Drug Delivery Reviews, 2021, 171, 48-49.	13.7	0
5	Eradication of Intracellular <i>Salmonella</i> Typhimurium by Polyplexes of Acidâ€Transforming Chitosan and Fragment DNA. Macromolecular Bioscience, 2021, 21, e2000408.	4.1	4
6	Discovery of New Imidazo[2,1- <i>b</i> ]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising <i>In Vitro</i> and <i>In Vivo</i> Anti-melanoma Activity. Journal of Medicinal Chemistry, 2021, 64, 6877-6901.	6.4	15
7	Temperature and pH-responsive in situ hydrogels of gelatin derivatives to prevent the reoccurrence of brain tumor. Biomedicine and Pharmacotherapy, 2021, 143, 112144.	5.6	11
8	Cancer nanotechnology: current status and perspectives. Nano Convergence, 2021, 8, 34.	12.1	97
9	Engineered extracellular vesicles and their mimetics for clinical translation. Methods, 2020, 177, 80-94.	3.8	26
10	Extracellular blebs: Artificially-induced extracellular vesicles for facile production and clinical translation. Methods, 2020, 177, 135-145.	3.8	33
11	Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications. ACS Nano, 2020, 14, 14262-14283.	14.6	33
12	Solvent-driven, self-assembled acid-responsive poly(ketalized serine)/siRNA complexes for RNA interference. Biomaterials Science, 2020, 8, 6718-6729.	5.4	2
13	Extracellular vesicles (EVs): Comprehensive packages with promises and complications for clinical translation and commercialization. Methods, 2020, 177, 1.	3.8	1
14	Biocompatible Chemotherapy for Leukemia by Acid-Cleavable, PEGylated FTY720. Bioconjugate Chemistry, 2020, 31, 673-684.	3.6	5
15	Aqueous-Soluble, Acid-Transforming Chitosan for Efficient and Stimuli-Responsive Gene Silencing. Biomacromolecules, 2018, 19, 1508-1516.	5.4	25
16	Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Progress in Retinal and Eye Research, 2018, 63, 107-131.	15.5	301
17	Stimuli-disassembling gold nanoclusters for diagnosis of early stage oral cancer by optical coherence tomography. Nano Convergence, 2018, 5, 3.	12.1	19
18	Cancer Cell-Derived, Drug-Loaded Nanovesicles Induced by Sulfhydryl-Blocking for Effective and Safe Cancer Therapy. ACS Nano, 2018, 12, 9568-9577.	14.6	71

#	Article	IF	CITATIONS
19	Aptamers: The "evolution―of SELEX. Methods, 2016, 106, 21-28.	3.8	117
20	Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery. Journal of Controlled Release, 2016, 241, 174-185.	9.9	129
21	Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation <i>via</i> Simultaneous Gene Transduction and Silencing. ACS Nano, 2016, 10, 8705-8714.	14.6	22
22	Design, challenge, and promise of stimuli-responsive nanoantibiotics. Nano Convergence, 2016, 3, 26.	12.1	25
23	Killing two birds or more with one stone. Advanced Drug Delivery Reviews, 2016, 98, 1-2.	13.7	3
24	"Combo―nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 3-18.	13.7	399
25	Facile synthesis of highâ€molecularâ€weight acidâ€labile polypeptides using urethane derivatives. Journal of Polymer Science Part A, 2015, 53, 280-286.	2.3	7
26	Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier. Journal of Biomedical Optics, 2014, 19, 105009.	2.6	21
27	Synthetically designed peptide-based biomaterials with stimuli-responsive and membrane-active properties for biomedical applications. Journal of Materials Chemistry B, 2014, 2, 595-615.	5.8	63
28	Stimuli-responsive siRNA carriers for efficient gene silencing in tumors via systemic delivery. Biomaterials Science, 2014, 2, 35-40.	5.4	12
29	Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene. Journal of Neuro-Oncology, 2014, 118, 29-37.	2.9	17
30	RNAi for silencing drug resistance in microbes toward development of nanoantibiotics. Journal of Controlled Release, 2014, 189, 150-157.	9.9	16
31	Photochemical internalization (PCI) enhanced nonviral transfection of tumor suppressor and pro-drug activating genes; a potential treatment modality for gliomas. Proceedings of SPIE, 2014, , .	0.8	0
32	Acid-degradable core–shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD). Biomaterials, 2013, 34, 10228-10237.	11.4	44
33	Imaging and quantifying Brownian motion of micro- and nanoparticles using phase-resolved Doppler variance optical coherence tomography. Journal of Biomedical Optics, 2013, 18, 030504.	2.6	8
34	Enhanced gene transfection by photochemical internalization of protomine sulfate/DNA complexes. , 2012, , .		1
35	Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Advanced Drug Delivery Reviews, 2012, 64, 1046-1059.	13.7	353
36	Before and after Endosomal Escape: Roles of Stimuli-Converting siRNA/Polymer Interactions in Determining Gene Silencing Efficiency. Accounts of Chemical Research, 2012, 45, 1077-1088.	15.6	105

#	Article	IF	CITATIONS
37	Glioma cell growth inhibition following photochemical internalization enhanced nonâ€viral PTEN gene transfection. Lasers in Surgery and Medicine, 2012, 44, 746-754.	2.1	12
38	Synthetically engineered viruses: Can synthetic chemistry tame the nature?. Current Opinion in Solid State and Materials Science, 2012, 16, 276-286.	11.5	3
39	siRNA as a conventional drug in the clinic? Challenges and current technologies. Drug Discovery Today: Technologies, 2012, 9, e167-e173.	4.0	10
40	Ketalized poly(amino ester) for stimuli-responsive and biocompatible gene delivery. Polymer Chemistry, 2012, 3, 2570.	3.9	14
41	Simultaneous gene transduction and silencing using stimuli-responsive viral/nonviral chimeric nanoparticles. Biomaterials, 2012, 33, 3316-3323.	11.4	30
42	Synthetically Functionalized Retroviruses Produced from the Bioorthogonally Engineered Cell Surface. Bioconjugate Chemistry, 2011, 22, 151-155.	3.6	7
43	Polyamine/DNA polyplexes with acid-degradable polymeric shell as structurally and functionally virus-mimicking nonviral vectors. Journal of Controlled Release, 2011, 150, 287-297.	9.9	33
44	"Nanoantibioticsâ€: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Journal of Controlled Release, 2011, 156, 128-145.	9.9	1,502
45	Dual mode polyspermine with tunable degradability for plasmid DNA and siRNA delivery. Biomaterials, 2011, 32, 4009-4020.	11.4	38
46	Separation and recovery of nucleic acids with improved biological activity by acidâ€degradable polyacrylamide gel electrophoresis. Electrophoresis, 2010, 31, 1656-1661.	2.4	6
47	Dynamics of nucleic acid/cationic polymer complexation and disassembly under biologically simulated conditions using in situ atomic force microscopy. Microscopy Research and Technique, 2010, 73, 845-856.	2.2	29
48	Acid-transforming polypeptide micelles for targeted nonviral gene delivery. Biomaterials, 2010, 31, 3404-3413.	11.4	73
49	Efficient and targeted delivery of siRNA <i>inâ€∫vivo</i> . FEBS Journal, 2010, 277, 4814-4827.	4.7	270
50	Enhanced detection of early-stage oral cancer in vivo by optical coherence tomography using multimodal delivery of gold nanoparticles. Journal of Biomedical Optics, 2009, 14, 034008.	2.6	125
51	Controlled cytoplasmic and nuclear localization of plasmid DNA and siRNA by differentially tailored polyethylenimine. Journal of Controlled Release, 2009, 133, 206-213.	9.9	75
52	Isolation of intact proteins from acidâ€degradable polyacrylamide gel. Proteomics, 2009, 9, 3765-3771.	2.2	6
53	Acid-Responsive Linear Polyethylenimine for Efficient, Specific, and Biocompatible siRNA Delivery. Bioconjugate Chemistry, 2009, 20, 488-499.	3.6	111
54	Acid-degradable cationic methacrylamide polymerized in the presence of plasmid DNA as tunable non-viral gene carrier. Biomaterials, 2008, 29, 3872-3881.	11.4	47

#	Article	IF	CITATIONS
55	Controlled Delivery of Plasmid DNA and siRNA to Intracellular Targets Using Ketalized Polyethylenimine. Biomacromolecules, 2008, 9, 444-455.	5.4	116
56	Differential Interaction of Retroviral Vector with Target Cell: Quantitative Effect of Cellular Receptor, Soluble Proteoglycan, and Cell Type on Gene Delivery Efficiency. Tissue Engineering - Part A, 2008, 14, 1497-1506.	3.1	0
57	Incorporation of CpG Oligonucleotide Ligand into Protein-Loaded Particle Vaccines Promotes Antigen-Specific CD8 T-Cell Immunity. Bioconjugate Chemistry, 2007, 18, 77-83.	3.6	60
58	Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. Journal of Controlled Release, 2005, 105, 199-212.	9.9	140
59	High-yield retroviral production using a temperature-modulated two-stage operation. Biotechnology and Bioengineering, 2005, 90, 365-372.	3.3	5
60	In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18264-18268.	7.1	200
61	Directed Antigen Presentation Using Polymeric Microparticulate Carriers Degradable at Lysosomal pH for Controlled Immune Responses. Molecular Pharmaceutics, 2005, 2, 83-91.	4.6	64
62	Acid-Degradable Particles for Protein-Based Vaccines:  Enhanced Survival Rate for Tumor-Challenged Mice Using Ovalbumin Model. Bioconjugate Chemistry, 2004, 15, 1281-1288.	3.6	82
63	Evaluation of Retroviral Production Systems Using Quantitative Analysis. Biotechnology Progress, 2003, 19, 528-537.	2.6	3
64	Determination of Infectious Retrovirus Concentration from Colony-Forming Assay with Quantitative Analysis. Journal of Virology, 2003, 77, 5712-5720.	3.4	63
65	Transduction rate constant as more reliable index quantifying efficiency of retroviral gene delivery. Biotechnology and Bioengineering, 2002, 77, 668-667.	3.3	14
66	Engineering Analysis of Ex Vivo Retroviral Transduction System. Annals of Biomedical Engineering, 2002, 30, 731-742.	2.5	5
67	Enhanced retroviral transduction of 293 cells cultured on liquid-liquid interfaces. Biotechnology and Bioengineering, 2001, 72, 331-338.	3.3	24
68	Impact of Cell Growth Morphology on Retroviral Transduction: Effect of Contact Inhibition. Biotechnology Progress, 2001, 17, 240-246.	2.6	11